# Grey Wolf Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/grey-wolf-therapeutics

- Industry: Biotechnology
- Headquarters: UK
- Website: www.greywolftherapeutics.com
- Total disclosed funding: $130M
- Latest round: Series B (May 23, 2024)
- Investors on record: 7

## About

Grey Wolf Therapeutics Limited, based in the UK, specializes in innovative antigen modulation technology designed to enhance immune system functionality, particularly in oncology.Founded in 2017 in the UK, Grey Wolf Therapeutics Limited focuses on developing advanced immunotherapies. The company, led by CEO Peter Joyce, has raised a total of USD 50.00 mn in funding, with its latest round being a Series B totaling USD 50.00 mn, led by Intermediate Capital Group on May 23, 2024. They have completed 7 deals to date.Grey Wolf Therapeutics focuses on innovative antigen modulation technology aimed at enhancing immune system functionality. Their flagship product, GRWD5769, is currently undergoing a Phase 1/2 clinical trial in oncology, demonstrating significant proof-of-mechanism and target engagement. This technology effectively modifies antigen presentation, enabling T cells to better recognize and target malignant or dysfunctional cells. The company's active discovery and development programs span multiple therapeutic areas, including oncology, autoimmunity, and virology, addressing significant unmet medical needs. Grey Wolf's offerings are positioned primarily in North America and Europe, with a target end-user base comprising healthcare providers, research institutions, and biopharmaceutical partners engaged in oncology and immunotherapy.Grey Wolf Therapeutics generates revenue through partnerships and collaborations with biopharmaceutical companies and research institutions, focusing on advancing their antigen modulation technology. The revenue model includes transaction structures based on milestone payments and royalties tied to the development and eventual commercialization of their lead product, GRWD5769, along with other pipeline candidates. The company engages in business-to-business (B2B) relationships, providing access to their proprietary technology and therapeutic solutions to partners involved in drug development. Specific pricing details for their products and services remain undisclosed, but they are structured around contracts that facilitate research and development efforts, aligning financial incentives with clinical progress and successful outcomes in their therapeutic areas.Grey Wolf Therapeutics plans to utilize the USD 50.00 mn raised in their recent Series B funding to expand its Phase 1/2 clinical trial of GRWD5769, an immuno-oncology candidate, and to further research treatments for autoimmune diseases. The company aims to accelerate the development of new products targeting significant unmet medical needs in these therapeutic areas. Additionally, Grey Wolf Therapeutics is exploring opportunities to enter new markets in North America and Europe, aiming to broaden their reach in the biopharmaceutical sector by 2025.

## Funding rounds

- Series B, May 23, 2024, $50M — Canaan Partners, Andera Partners, Earlybird, Pfizer Venture Investments, Oxford Sciences Enterprises, British Patient Capital, Intermediate Capital Group, Inc
- Series B, Jan 26, 2023, $49M — Canaan Partners, Andera Partners, Earlybird, Pfizer Venture Investments, Oxford Sciences Enterprises, British Patient Capital
- Series A, Oct 8, 2021, $4.9M — Canaan Partners
- Series A, Nov 20, 2020, $8.8M — Canaan Partners
- Series A, Jan 9, 2020, $3.3M — Canaan Partners, Andera Partners
- Series A, Mar 29, 2018, $14M — Canaan Partners, Andera Partners

## Investors

- Canaan Partners (https://capitalatlas.ai/funds/canaan-partners) — Series A, Series B
- Andera Partners (https://capitalatlas.ai/funds/andera-partners) — Series A, Series B
- Earlybird (https://capitalatlas.ai/funds/earlybird) — Series B
- Pfizer Venture Investments (https://capitalatlas.ai/funds/pfizer-venture-investments) — Series B
- Oxford Sciences Enterprises (https://capitalatlas.ai/funds/oxford-sciences-enterprises) — Series B
- British Patient Capital — Series B
- Intermediate Capital Group, Inc — Series B